科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background. Gaucher disease is an autosomal recessive lysosomal glycosphingolipid storage disorder resulting from a deficiency of lysosomal enzyme acid beta-glucosidase (glucocerebrosidase). This partial enzyme deficiency results in accumulation of glycosphingolipid-laden macrophages (Gaucher cells) throughout the liver, spleen, bone marrow, skeleton, lungs and brain (only in types 2 and 3).
Objective. These guidelines aim to provide a standard of care for patients with Gaucher disease in keeping with international standards, but also realistic for South Africa, and to provide a shared-care model for treating physicians and funders regarding care for these patients.
Recommendations. All healthcare professionals involved in the diagnosis and management of Gaucher disease should take. note of and implement these guidelines in clinical practice as far as possible.
Validation. These guidelines were developed through consensus by the Lysosomal Storage Disorder Medical Advisory Board. They are largely based on the UK 2005 National Guidelines for Gaucher Disease, but include new treatment recommendations for enzyme replacement therapy based on subsequent publications. The Southern African Society for Human Genetics (SASHG) (who have endorsed the guidelines) and the National Osteoporosis Foundation of South Africa (NOFSA) provided valuable input.
Guidelines sponsor. Genzyme initiated the project and sponsored the meetings of the Advisory Board and all costs generated by these meetings.
Conclusion. It is intended that these guidelines will enable all patients suffering from Gaucher disease to be diagnosed and offered the best possible care available. S Afr Med J 2012;102(8):697-702. DOI:10.7196/SAMJ.5439
- 出版日期2012-8
